Remember Biology 101? I sure do. It was the first class I had in my first semester in college at the ripe age of 18. It started at 7:30 in the morning, whether or not I did, and was taught by one of ...

G.E. Ward, M.W. Kirschner, "Identification of cell cycle- regulated phosphorylation sites on nuclear lamin C," Cell, 61:561-77, 1990. Marc Kirschner (University of California, San Francisco): "It is ...

"We had previously demonstrated that the p53 gene product--the most commonly mutated gene in human cancer--controls cell-cycle arrest in response to damage," says Kastan. In this paper the authors ...

Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin ...

SAN DIEGO--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that ...

FLORHAM PARK, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell ...

Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients. Beam Therapeutics Inc. has announced that it will present updated ...

If the gene therapy treatment is proven to be effective in curing the sickle cell disease, it will initially be made available to people with severe sickle cell disease, maybe with organ damage.